Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rheumatology | 6 | 2023 | 109 | 1.780 |
Why?
|
| Arthritis, Juvenile | 4 | 2023 | 38 | 1.660 |
Why?
|
| Lupus Erythematosus, Systemic | 5 | 2024 | 169 | 0.840 |
Why?
|
| Teratogens | 1 | 2023 | 87 | 0.820 |
Why?
|
| Pregnancy in Adolescence | 1 | 2023 | 49 | 0.820 |
Why?
|
| Biomedical Research | 1 | 2022 | 510 | 0.530 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 3 | 2022 | 73 | 0.510 |
Why?
|
| Immunosuppressive Agents | 6 | 2022 | 645 | 0.430 |
Why?
|
| Pediatrics | 1 | 2022 | 1137 | 0.410 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2022 | 141 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 1015 | 0.260 |
Why?
|
| Hodgkin Disease | 1 | 2008 | 293 | 0.250 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 669 | 0.250 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 771 | 0.250 |
Why?
|
| Lymphedema | 1 | 2004 | 19 | 0.240 |
Why?
|
| Lupus Nephritis | 2 | 2017 | 44 | 0.240 |
Why?
|
| Mycophenolic Acid | 2 | 2017 | 51 | 0.240 |
Why?
|
| Frameshift Mutation | 1 | 2004 | 175 | 0.230 |
Why?
|
| Economics, Behavioral | 1 | 2023 | 6 | 0.210 |
Why?
|
| Contraception | 1 | 2023 | 59 | 0.200 |
Why?
|
| Antirheumatic Agents | 1 | 2023 | 117 | 0.190 |
Why?
|
| Histoplasmosis | 1 | 2021 | 46 | 0.190 |
Why?
|
| Rheumatic Diseases | 1 | 2021 | 67 | 0.180 |
Why?
|
| Health Equity | 1 | 2022 | 54 | 0.180 |
Why?
|
| Stomatitis, Aphthous | 1 | 2020 | 3 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2024 | 333 | 0.180 |
Why?
|
| Kidney Diseases | 1 | 2004 | 477 | 0.180 |
Why?
|
| Pharyngitis | 1 | 2020 | 31 | 0.180 |
Why?
|
| Lymphadenitis | 1 | 2020 | 26 | 0.170 |
Why?
|
| Quality Improvement | 2 | 2023 | 621 | 0.170 |
Why?
|
| Pneumococcal Vaccines | 1 | 2020 | 168 | 0.150 |
Why?
|
| Fever | 1 | 2020 | 296 | 0.140 |
Why?
|
| Pneumococcal Infections | 1 | 2020 | 274 | 0.140 |
Why?
|
| Documentation | 1 | 2018 | 115 | 0.140 |
Why?
|
| Humans | 19 | 2024 | 122633 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 845 | 0.130 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 2047 | 0.130 |
Why?
|
| Child | 11 | 2023 | 24086 | 0.130 |
Why?
|
| Electronic Health Records | 2 | 2020 | 697 | 0.120 |
Why?
|
| Transcription Factors | 1 | 2004 | 2575 | 0.120 |
Why?
|
| Vaccination | 1 | 2020 | 949 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 317 | 0.120 |
Why?
|
| Adolescent | 5 | 2024 | 18987 | 0.110 |
Why?
|
| Algorithms | 1 | 2020 | 1583 | 0.100 |
Why?
|
| Psychotic Disorders | 1 | 2013 | 140 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 710 | 0.100 |
Why?
|
| Remission Induction | 1 | 2012 | 300 | 0.090 |
Why?
|
| Hydroxychloroquine | 1 | 2011 | 18 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 62 | 0.090 |
Why?
|
| Oligonucleotides | 1 | 2011 | 88 | 0.090 |
Why?
|
| Virus Diseases | 1 | 2013 | 280 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2013 | 305 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2022 | 242 | 0.090 |
Why?
|
| Pregnancy | 1 | 2023 | 7105 | 0.090 |
Why?
|
| Rituximab | 1 | 2011 | 156 | 0.090 |
Why?
|
| Patient Participation | 1 | 2022 | 218 | 0.080 |
Why?
|
| Female | 7 | 2024 | 65117 | 0.080 |
Why?
|
| Sialyltransferases | 1 | 2008 | 6 | 0.080 |
Why?
|
| Consensus | 1 | 2022 | 606 | 0.080 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 420 | 0.080 |
Why?
|
| Etanercept | 1 | 2008 | 39 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 64 | 0.080 |
Why?
|
| Infliximab | 1 | 2008 | 67 | 0.080 |
Why?
|
| Evidence-Based Medicine | 2 | 2022 | 611 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 501 | 0.070 |
Why?
|
| Age of Onset | 2 | 2020 | 581 | 0.060 |
Why?
|
| Multiple Sclerosis | 1 | 2008 | 334 | 0.060 |
Why?
|
| 5' Untranslated Regions | 1 | 2004 | 59 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 713 | 0.060 |
Why?
|
| DNA Primers | 1 | 2004 | 661 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2021 | 13794 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2004 | 370 | 0.050 |
Why?
|
| Young Adult | 3 | 2024 | 8817 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2008 | 1471 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 805 | 0.050 |
Why?
|
| Retreatment | 1 | 2021 | 88 | 0.050 |
Why?
|
| Pedigree | 1 | 2004 | 1579 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2023 | 213 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 1334 | 0.050 |
Why?
|
| Cimetidine | 1 | 2020 | 14 | 0.040 |
Why?
|
| Tubulin Modulators | 1 | 2020 | 10 | 0.040 |
Why?
|
| Antipyretics | 1 | 2020 | 9 | 0.040 |
Why?
|
| Colchicine | 1 | 2020 | 43 | 0.040 |
Why?
|
| Base Sequence | 1 | 2004 | 3093 | 0.040 |
Why?
|
| Nursing Staff | 1 | 2020 | 13 | 0.040 |
Why?
|
| Male | 6 | 2021 | 59714 | 0.040 |
Why?
|
| Histamine H2 Antagonists | 1 | 2020 | 49 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 42 | 0.040 |
Why?
|
| Vaccines, Conjugate | 1 | 2020 | 78 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2020 | 148 | 0.040 |
Why?
|
| DNA | 1 | 2004 | 1591 | 0.040 |
Why?
|
| Pharmacists | 1 | 2020 | 83 | 0.040 |
Why?
|
| Neck | 1 | 2020 | 138 | 0.040 |
Why?
|
| Infant | 2 | 2018 | 12272 | 0.040 |
Why?
|
| Tonsillectomy | 1 | 2020 | 96 | 0.040 |
Why?
|
| Research Design | 1 | 2022 | 654 | 0.040 |
Why?
|
| Rheumatologists | 1 | 2017 | 9 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 3079 | 0.040 |
Why?
|
| Nephrologists | 1 | 2017 | 13 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 419 | 0.040 |
Why?
|
| Syndrome | 1 | 2020 | 1111 | 0.040 |
Why?
|
| Pediatricians | 1 | 2017 | 65 | 0.030 |
Why?
|
| United States | 2 | 2022 | 10559 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 284 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 249 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 546 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 590 | 0.030 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2018 | 274 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2788 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1248 | 0.030 |
Why?
|
| Echocardiography | 1 | 2018 | 1069 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1864 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 1466 | 0.020 |
Why?
|
| Phenotype | 1 | 2018 | 4200 | 0.020 |
Why?
|
| Australia | 1 | 2008 | 142 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2008 | 306 | 0.020 |
Why?
|
| Kidney | 1 | 2013 | 1337 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 2837 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 15916 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 12055 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 2584 | 0.010 |
Why?
|
| Adult | 1 | 2020 | 28881 | 0.010 |
Why?
|
| Risk Factors | 1 | 2008 | 9943 | 0.010 |
Why?
|
YILDIRIM TORUNER's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(123)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(4)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_